Mucormycosis is a rare but fatal fungal infection with low survival rate in immune-compromised patients. It is caused by a fungus belonging to the Mucoraceae family of the Zygomycetes class. Mucormycosis is classified as rhino-orbital-cerebral, pulmonary, cutaneous, gastrointestinal, disseminated, and miscellaneous types according to its clinical manifestations. Early diagnosis and treatment along with correction of the underlying medical condition is important for favorable results. This case presentation describes mucormycosis involving the anterior maxillary region in a leukemic patient with prolonged neutropenia. The patient benefited from a timely biopsy and immediate treatment with amphotericin B, and was successfully managed with an interdisciplinary team approach consisting of dental and several medical specialists.
Hospital, for further hematologic evaluation due to a finding of pancytopenia in his blood studies. Initial hematologic screening showed low blood cell counts (white blood cell Absidia genera have been associated with human diseases.
Overall, the Rhizopus genus is the most commonly implicated organism causing mucormycosis in humans, accounting for 90% of infections. 15) Infection usually occurs by inhalation through the respiratory route or by direct skin contact. When spores come into one's body with normal immunity, their proliferation is inhibited by the immunologic functions of macrophages, neutrophils, and complements. But in immune-suppressed patients, fungi rapidly proliferate and the characteristic tissue responses such as thrombus formation, infarction, and necrosis are provoked. 15) Clinical manifestations are varied and mucormycosis is classified as rhino-orbital-cerebral, pulmonary, cutaneous, gastrointestinal, disseminated, and miscellaneous types. In patients with diabetes, rhino-orbital-cerebral mucormycosis is common and the pulmonary type is rare. 10) Lung infection with the rhino-orbital-cerebral type often occurs in patients with neutropenia. [15] [16] [17] Dissemination of fungal hyphae along the blood stream to major organs such as brain and lung can lead to death. Aspergillosis is the second most common fungal infection, followed by mucormycosis. Such primary diseases and systemic conditions, as predisposing factors, make a favorable environment for fungal infection. In the present case, mucormycosis developed in a patient with acute leukemia and preceding neutropenia.
The pathogens that cause mucormycosis are commonly found in the environment-organic debris decaying in soil, leaves, fruits, rotten wood, and composts. In the Mucoraceae family of the Zygomycetes class, the Rhizopus, Mucor, and Long-term use of amphotericin B is necessary because it is not fungicidal but fungistatic. 21) It is usually administered for two to three months although the exact treatment period, and the total dose varies according to the factors, including the patient's response and the degree of renal toxicity. Side effects of amphotericin B include fever, nausea, vomiting, hypokalemia, and nephrotoxicity. To prevent such side effects, acetaminophen, diphenhydramine, and hydrocortisone can be administrated as pre-treatment. [21] [22] [23] [24] [25] [26] Posaconazole has demonstrated treatment efficacy in the case of mucormycosis experimentally induced by Mucor but not by Rhizopus. According to some reports, 27, 28) is also valuable at the early stage of disease progression when the result of the blood culture is negative. 15, 24) The widely accepted method of managing mucormycosis is a multi-faceted treatment strategy including administration of proper antifungal agents, correction or removal of the underlying disease, and surgical excision of necrotic tissues. The treatment results largely depend on the degree of immune suppression, infection depths and sites, the time until suitable treatment is provided, and the form of treatment. According to Blitzer et al., 19) the survival rate of rhino-orbital-cerebral mucormycosis was 75% without systemic disease, 60% in patients with diabetes, and only 20%
when it accompanies other systemic diseases.
The underlying disease must be corrected before surgical procedures are performed. For example, hyperglycemia in patients with diabetic acidosis needs to be actively corrected. In transplant recipients and patients with blood cancer, corticosteroids or other immunosuppressive agents should be temporarily stopped until the infection is controlled.
For the recovery of immune function, administration of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and interferon-α can be considered. G-CSF and GM-CSF facilitate the generation of neutrophils and various immune cells, and promote the effect of the antifungal agent. 25) Amphotericin B is the first drug of choice for mucor mycosis.
